Impact of age, sex and medical history on adverse reactions to the first and second dose of BNT162b2 mRNA COVID-19 vaccine in Japan: a cross-sectional study

go back to reference Coronavirus disease (COVID-19). Weekly epidemiological update and weekly operational update. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports. Coronavirus disease (COVID-19). Weekly epidemiological update and weekly operational update. https://​www.​who.​int/​emergencies/​diseases/​novel-coronavirus-2019/​situation-reports.

go back to reference Jayaweera M, Perera H, Gunawardana B, Manatunge J. Transmission of COVID-19 virus by droplets and aerosols: a critical review on the unresolved dichotomy. Environ Res. 2020;188:109819. https://doi.org/10.1016/j.envres.2020.109819.CrossRefPubMedPubMedCentral Jayaweera M, Perera H, Gunawardana B, Manatunge J. Transmission of COVID-19 virus by droplets and aerosols: a critical review on the unresolved dichotomy. Environ Res. 2020;188:109819. https://​doi.​org/​10.​1016/​j.​envres.​2020.​109819.CrossRefPubMedPubMedCentral

go back to reference Transmission of SARS-CoV-2: implications for infection prevention precautions. https://www.who.int/news-room/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-prevention-precautions. Transmission of SARS-CoV-2: implications for infection prevention precautions. https://​www.​who.​int/​news-room/​commentaries/​detail/​transmission-of-sars-cov-2-implications-for-infection-prevention-precautions.

go back to reference Scientific brief: SARS-CoV-2 transmission. https://www.cdc.gov/coronavirus/2019-ncov/science/science-briefs/sars-cov-2-transmission.html. Scientific brief: SARS-CoV-2 transmission. https://​www.​cdc.​gov/​coronavirus/​2019-ncov/​science/​science-briefs/​sars-cov-2-transmission.​html.

go back to reference Centers for Disease Control and Prevention. Symptoms of COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html. Updated 22 Feb 2021. Centers for Disease Control and Prevention. Symptoms of COVID-19. https://​www.​cdc.​gov/​coronavirus/​2019-ncov/​symptoms-testing/​symptoms.​html. Updated 22 Feb 2021.

go back to reference Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, Sinn BV, Gerhold M, Hauptmann K, Ingold-Heppner B, Miller F, Herbst H, Corman VM, Martin H, Radbruch H, Heppner FL, Horst D. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep. 2021;11(1):4263. https://doi.org/10.1038/s41598-021-82862-5.CrossRefPubMedPubMedCentral Elezkurtaj S, Greuel S, Ihlow J, Michaelis EG, Bischoff P, Kunze CA, Sinn BV, Gerhold M, Hauptmann K, Ingold-Heppner B, Miller F, Herbst H, Corman VM, Martin H, Radbruch H, Heppner FL, Horst D. Causes of death and comorbidities in hospitalized patients with COVID-19. Sci Rep. 2021;11(1):4263. https://​doi.​org/​10.​1038/​s41598-021-82862-5.CrossRefPubMedPubMedCentral

go back to reference Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782–93. https://doi.org/10.1001/jama.2020.12839.CrossRefPubMed Wiersinga WJ, Rhodes A, Cheng AC, Peacock SJ, Prescott HC. Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;324(8):782–93. https://​doi.​org/​10.​1001/​jama.​2020.​12839.CrossRefPubMed

go back to reference Tindale LC, Stockdale JE, Coombe M, Garlock ES, Lau WYV, Saraswat M, Zhang L, Chen D, Wallinga J, Colijn C. Evidence for transmission of COVID-19 prior to symptom onset. Elife. 2020;9:e57149. https://doi.org/10.7554/eLife.57149.CrossRefPubMedPubMedCentral Tindale LC, Stockdale JE, Coombe M, Garlock ES, Lau WYV, Saraswat M, Zhang L, Chen D, Wallinga J, Colijn C. Evidence for transmission of COVID-19 prior to symptom onset. Elife. 2020;9:e57149. https://​doi.​org/​10.​7554/​eLife.​57149.CrossRefPubMedPubMedCentral

go back to reference Al-Sadeq DW, Nasrallah GK. The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: a systematic review. Int J Infect Dis. 2020;98:372–80. https://doi.org/10.1016/j.ijid.2020.06.098 (Epub 2020 Jul 2).CrossRefPubMedPubMedCentral Al-Sadeq DW, Nasrallah GK. The incidence of the novel coronavirus SARS-CoV-2 among asymptomatic patients: a systematic review. Int J Infect Dis. 2020;98:372–80. https://​doi.​org/​10.​1016/​j.​ijid.​2020.​06.​098 (Epub 2020 Jul 2).CrossRefPubMedPubMedCentral

go back to reference Coclite D, Napoletano A, Gianola S, Del Monaco A, D’Angelo D, Fauci A, Iacorossi L, Latina R, Torre G, Mastroianni CM, Renzi C, Castellini G, Iannone P. Face mask use in the community for reducing the spread of COVID-19: a systematic review. Front Med (Lausanne). 2021;7:594269. https://doi.org/10.3389/fmed.2020.594269 (eCollection 2020).CrossRef Coclite D, Napoletano A, Gianola S, Del Monaco A, D’Angelo D, Fauci A, Iacorossi L, Latina R, Torre G, Mastroianni CM, Renzi C, Castellini G, Iannone P. Face mask use in the community for reducing the spread of COVID-19: a systematic review. Front Med (Lausanne). 2021;7:594269. https://​doi.​org/​10.​3389/​fmed.​2020.​594269 (eCollection 2020).CrossRef

go back to reference Veys K, Dockx K, Van Remoortel H, Vandekerckhove P, De Buck E. The effect of hand hygiene promotion programs during epidemics and pandemics of respiratory droplet-transmissible infections on health outcomes: a rapid systematic review. BMC Public Health. 2021;21(1):1745. https://doi.org/10.1186/s12889-021-11815-4.CrossRefPubMedPubMedCentral Veys K, Dockx K, Van Remoortel H, Vandekerckhove P, De Buck E. The effect of hand hygiene promotion programs during epidemics and pandemics of respiratory droplet-transmissible infections on health outcomes: a rapid systematic review. BMC Public Health. 2021;21(1):1745. https://​doi.​org/​10.​1186/​s12889-021-11815-4.CrossRefPubMedPubMedCentral

go back to reference Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ, COVID-19 Systematic Urgent Review Group Effort (SURGE) Study Authors. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395(10242):1973–87. https://doi.org/10.1016/S0140-6736(20)31142-9 (Epub 2020 Jun 1).CrossRefPubMedPubMedCentral Chu DK, Akl EA, Duda S, Solo K, Yaacoub S, Schünemann HJ, COVID-19 Systematic Urgent Review Group Effort (SURGE) Study Authors. Physical distancing, face masks, and eye protection to prevent person-to-person transmission of SARS-CoV-2 and COVID-19: a systematic review and meta-analysis. Lancet. 2020;395(10242):1973–87. https://​doi.​org/​10.​1016/​S0140-6736(20)31142-9 (Epub 2020 Jun 1).CrossRefPubMedPubMedCentral

go back to reference Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Şahin U, Jansen KU. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589–93. https://doi.org/10.1038/s41586-020-2639-4 (Epub 2020 Aug 12).CrossRefPubMed Mulligan MJ, Lyke KE, Kitchin N, Absalon J, Gurtman A, Lockhart S, Neuzil K, Raabe V, Bailey R, Swanson KA, Li P, Koury K, Kalina W, Cooper D, Fontes-Garfias C, Shi PY, Türeci Ö, Tompkins KR, Walsh EE, Frenck R, Falsey AR, Dormitzer PR, Gruber WC, Şahin U, Jansen KU. Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults. Nature. 2020;586(7830):589–93. https://​doi.​org/​10.​1038/​s41586-020-2639-4 (Epub 2020 Aug 12).CrossRefPubMed

go back to reference Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. https://doi.org/10.1056/NEJMoa2034577 (Epub 2020 Dec 10).CrossRefPubMed Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, Perez JL, Pérez Marc G, Moreira ED, Zerbini C, Bailey R, Swanson KA, Roychoudhury S, Koury K, Li P, Kalina WV, Cooper D, Frenck RW Jr, Hammitt LL, Türeci Ö, Nell H, Schaefer A, Ünal S, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–15. https://​doi.​org/​10.​1056/​NEJMoa2034577 (Epub 2020 Dec 10).CrossRefPubMed

go back to reference Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T, COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16. https://doi.org/10.1056/NEJMoa2035389 (Epub 2020 Dec 30).CrossRefPubMed Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, McGettigan J, Khetan S, Segall N, Solis J, Brosz A, Fierro C, Schwartz H, Neuzil K, Corey L, Gilbert P, Janes H, Follmann D, Marovich M, Mascola J, Polakowski L, Ledgerwood J, Graham BS, Bennett H, Pajon R, Knightly C, Leav B, Deng W, Zhou H, Han S, Ivarsson M, Miller J, Zaks T, COVE Study Group. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021;384(5):403–16. https://​doi.​org/​10.​1056/​NEJMoa2035389 (Epub 2020 Dec 30).CrossRefPubMed

go back to reference Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O’Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ, Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. https://doi.org/10.1016/S0140-6736(20)32661-1 (Epub 2020 Dec 8).CrossRefPubMedPubMedCentral Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, Angus B, Baillie VL, Barnabas SL, Bhorat QE, Bibi S, Briner C, Cicconi P, Collins AM, Colin-Jones R, Cutland CL, Darton TC, Dheda K, Duncan CJA, Emary KRW, Ewer KJ, Fairlie L, Faust SN, Feng S, Ferreira DM, Finn A, Goodman AL, Green CM, Green CA, Heath PT, Hill C, Hill H, Hirsch I, Hodgson SHC, Izu A, Jackson S, Jenkin D, Joe CCD, Kerridge S, Koen A, Kwatra G, Lazarus R, Lawrie AM, Lelliott A, Libri V, Lillie PJ, Mallory R, Mendes AVA, Milan EP, Minassian AM, McGregor A, Morrison H, Mujadidi YF, Nana A, O’Reilly PJ, Padayachee SD, Pittella A, Plested E, Pollock KM, Ramasamy MN, Rhead S, Schwarzbold AV, Singh N, Smith A, Song R, Snape MD, Sprinz E, Sutherland RK, Tarrant R, Thomson EC, Török ME, Toshner M, Turner DPJ, Vekemans J, Villafana TL, Watson MEE, Williams CJ, Douglas AD, Hill AVS, Lambe T, Gilbert SC, Pollard AJ, Oxford COVID Vaccine Trial Group. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397(10269):99–111. https://​doi.​org/​10.​1016/​S0140-6736(20)32661-1 (Epub 2020 Dec 8).CrossRefPubMedPubMedCentral

go back to reference Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, Offergeld K, Scheper G, Taylor KL, Robb ML, Treanor J, Barouch DH, Stoddard J, Ryser MF, Marovich MA, Neuzil KM, Corey L, Cauwenberghs N, Tanner T, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M, ENSEMBLE Study Group. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–201. https://doi.org/10.1056/NEJMoa2101544 (Epub 2021 Apr 21).CrossRefPubMed Sadoff J, Gray G, Vandebosch A, Cárdenas V, Shukarev G, Grinsztejn B, Goepfert PA, Truyers C, Fennema H, Spiessens B, Offergeld K, Scheper G, Taylor KL, Robb ML, Treanor J, Barouch DH, Stoddard J, Ryser MF, Marovich MA, Neuzil KM, Corey L, Cauwenberghs N, Tanner T, Hardt K, Ruiz-Guiñazú J, Le Gars M, Schuitemaker H, Van Hoof J, Struyf F, Douoguih M, ENSEMBLE Study Group. Safety and efficacy of single-dose Ad26.COV2.S vaccine against Covid-19. N Engl J Med. 2021;384(23):2187–201. https://​doi.​org/​10.​1056/​NEJMoa2101544 (Epub 2021 Apr 21).CrossRefPubMed

go back to reference Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, Köse Ş, Erdinç FŞ, Akalın EH, Tabak ÖF, Pullukçu H, Batum Ö, Şimşek Yavuz S, Turhan Ö, Yıldırmak MT, Köksal İ, Taşova Y, Korten V, Yılmaz G, Çelen MK, Altın S, Çelik İ, Bayındır Y, Karaoğlan İ, Yılmaz A, Özkul A, Gür H, Unal S, CoronaVac Study Group. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213–22. https://doi.org/10.1016/S0140-6736(21)01429-X (Epub 2021 Jul 8).CrossRefPubMedPubMedCentral Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, Köse Ş, Erdinç FŞ, Akalın EH, Tabak ÖF, Pullukçu H, Batum Ö, Şimşek Yavuz S, Turhan Ö, Yıldırmak MT, Köksal İ, Taşova Y, Korten V, Yılmaz G, Çelen MK, Altın S, Çelik İ, Bayındır Y, Karaoğlan İ, Yılmaz A, Özkul A, Gür H, Unal S, CoronaVac Study Group. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021;398(10296):213–22. https://​doi.​org/​10.​1016/​S0140-6736(21)01429-X (Epub 2021 Jul 8).CrossRefPubMedPubMedCentral

go back to reference Kadali RAK, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID-19 vaccine: a randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis. 2021;106:376–81. https://doi.org/10.1016/j.ijid.2021.04.047 (Epub 2021 Apr 15).CrossRefPubMedPubMedCentral Kadali RAK, Janagama R, Peruru S, Malayala SV. Side effects of BNT162b2 mRNA COVID-19 vaccine: a randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers. Int J Infect Dis. 2021;106:376–81. https://​doi.​org/​10.​1016/​j.​ijid.​2021.​04.​047 (Epub 2021 Apr 15).CrossRefPubMedPubMedCentral

go back to reference Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, Walter EB, Senders S, Bailey R, Swanson KA, Ma H, Xu X, Koury K, Kalina WV, Cooper D, Jennings T, Brandon DM, Thomas SJ, Türeci Ö, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239–50. https://doi.org/10.1056/NEJMoa2107456 (Epub 2021 May 27).CrossRefPubMed Frenck RW Jr, Klein NP, Kitchin N, Gurtman A, Absalon J, Lockhart S, Perez JL, Walter EB, Senders S, Bailey R, Swanson KA, Ma H, Xu X, Koury K, Kalina WV, Cooper D, Jennings T, Brandon DM, Thomas SJ, Türeci Ö, Tresnan DB, Mather S, Dormitzer PR, Şahin U, Jansen KU, Gruber WC, C4591001 Clinical Trial Group. Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents. N Engl J Med. 2021;385(3):239–50. https://​doi.​org/​10.​1056/​NEJMoa2107456 (Epub 2021 May 27).CrossRefPubMed

go back to reference Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–23. https://doi.org/10.1056/NEJMoa2101765 (Epub 2021 Feb 24).CrossRefPubMed Dagan N, Barda N, Kepten E, Miron O, Perchik S, Katz MA, Hernán MA, Lipsitch M, Reis B, Balicer RD. BNT162b2 mRNA covid-19 vaccine in a nationwide mass vaccination setting. N Engl J Med. 2021;384(15):1412–23. https://​doi.​org/​10.​1056/​NEJMoa2101765 (Epub 2021 Feb 24).CrossRefPubMed

go back to reference Hoffmann MA, Wieler HJ, Enders P, Buchholz HG, Plachter B. Age- and sex-graded data evaluation of vaccination reactions after initial injection of the BNT162b2 mRNA vaccine in a local vaccination center in Germany. Vaccines (Basel). 2021;9(8):911. https://doi.org/10.3390/vaccines9080911.CrossRef Hoffmann MA, Wieler HJ, Enders P, Buchholz HG, Plachter B. Age- and sex-graded data evaluation of vaccination reactions after initial injection of the BNT162b2 mRNA vaccine in a local vaccination center in Germany. Vaccines (Basel). 2021;9(8):911. https://​doi.​org/​10.​3390/​vaccines9080911.CrossRef

go back to reference Bae S, Lee YW, Lim SY, Lee JH, Lim JS, Lee S, Park S, Kim SK, Lim YJ, Kim EO, Jung J, Kwon HS, Kim TB, Kim SH. Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea. J Korean Med Sci. 2021;36(17): e115. https://doi.org/10.3346/jkms.2021.36.e115.CrossRefPubMedPubMedCentral Bae S, Lee YW, Lim SY, Lee JH, Lim JS, Lee S, Park S, Kim SK, Lim YJ, Kim EO, Jung J, Kwon HS, Kim TB, Kim SH. Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea. J Korean Med Sci. 2021;36(17): e115. https://​doi.​org/​10.​3346/​jkms.​2021.​36.​e115.CrossRefPubMedPubMedCentral

go back to reference Lee YW, Lim SY, Lee JH, Lim JS, Kim M, Kwon S, Joo J, Kwak SH, Kim EO, Jung J, Kwon HS, Kim TB, Kim SH, Bae S. Adverse reactions of the second dose of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in Korea. J Korean Med Sci. 2021;36(21): e153. https://doi.org/10.3346/jkms.2021.36.e153.CrossRefPubMedPubMedCentral Lee YW, Lim SY, Lee JH, Lim JS, Kim M, Kwon S, Joo J, Kwak SH, Kim EO, Jung J, Kwon HS, Kim TB, Kim SH, Bae S. Adverse reactions of the second dose of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in Korea. J Korean Med Sci. 2021;36(21): e153. https://​doi.​org/​10.​3346/​jkms.​2021.​36.​e153.CrossRefPubMedPubMedCentral

go back to reference Ossato A, Tessari R, Trabucchi C, Zuppini T, Realdon N, Marchesini F. Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021. Eur J Hosp Pharm. 2021. https://doi.org/10.1136/ejhpharm-2021-002933 (Online ahead of print).CrossRefPubMed Ossato A, Tessari R, Trabucchi C, Zuppini T, Realdon N, Marchesini F. Comparison of medium-term adverse reactions induced by the first and second dose of mRNA BNT162b2 (Comirnaty, Pfizer-BioNTech) vaccine: a post-marketing Italian study conducted between 1 January and 28 February 2021. Eur J Hosp Pharm. 2021. https://​doi.​org/​10.​1136/​ejhpharm-2021-002933 (Online ahead of print).CrossRefPubMed

go back to reference Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 2019;32(2):e00084-18. https://doi.org/10.1128/CMR.00084-18 (Print 2019 Mar 20).CrossRefPubMedPubMedCentral Zimmermann P, Curtis N. Factors that influence the immune response to vaccination. Clin Microbiol Rev. 2019;32(2):e00084-18. https://​doi.​org/​10.​1128/​CMR.​00084-18 (Print 2019 Mar 20).CrossRefPubMedPubMedCentral

go back to reference Potluri T, Fink AL, Sylvia KE, Dhakal S, Vermillion MS, Vom Steeg L, Deshpande S, Narasimhan H, Klein SL. Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females. NPJ Vaccines. 2019;4:29. https://doi.org/10.1038/s41541-019-0124-6 (eCollection 2019).CrossRefPubMedPubMedCentral Potluri T, Fink AL, Sylvia KE, Dhakal S, Vermillion MS, Vom Steeg L, Deshpande S, Narasimhan H, Klein SL. Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females. NPJ Vaccines. 2019;4:29. https://​doi.​org/​10.​1038/​s41541-019-0124-6 (eCollection 2019).CrossRefPubMedPubMedCentral

go back to reference Venkatakrishnan AJ, Praveen Kumar M, Silvert E, Garcia-Rivera E, Szenk M, Suratekar R, Lenehan P, Lindemer E, O’Horo JC, Williams AW, Badley AD, Virk A, Swift MD, Gores GJ, Soundararajan V. Female-male differences in COVID vaccine adverse events have precedence in seasonal flu shots: a potential link to sex-associated baseline gene expression patterns. https://doi.org/10.1101/2021.04.01.21254798. Venkatakrishnan AJ, Praveen Kumar M, Silvert E, Garcia-Rivera E, Szenk M, Suratekar R, Lenehan P, Lindemer E, O’Horo JC, Williams AW, Badley AD, Virk A, Swift MD, Gores GJ, Soundararajan V. Female-male differences in COVID vaccine adverse events have precedence in seasonal flu shots: a potential link to sex-associated baseline gene expression patterns. https://​doi.​org/​10.​1101/​2021.​04.​01.​21254798.

go back to reference Nikolich-Žugich J. The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol. 2018;19(1):10–9. https://doi.org/10.1038/s41590-017-0006-x (Epub 2017 Dec 14).CrossRefPubMed Nikolich-Žugich J. The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol. 2018;19(1):10–9. https://​doi.​org/​10.​1038/​s41590-017-0006-x (Epub 2017 Dec 14).CrossRefPubMed

go back to reference Vassilaki N, Gargalionis AN, Bletsa A, Papamichalopoulos N, Kontou E, Gkika M, Patas K, Theodoridis D, Manolis I, Ioannidis A, Milona RS, Tsirogianni A, Angelakis E, Chatzipanagiotou S. Impact of age and sex on antibody response following the second Dose of COVID-19 BNT162b2 mRNA vaccine in Greek healthcare workers. Microorganisms. 2021;9(8):1725. https://doi.org/10.3390/microorganisms9081725.CrossRefPubMedPubMedCentral Vassilaki N, Gargalionis AN, Bletsa A, Papamichalopoulos N, Kontou E, Gkika M, Patas K, Theodoridis D, Manolis I, Ioannidis A, Milona RS, Tsirogianni A, Angelakis E, Chatzipanagiotou S. Impact of age and sex on antibody response following the second Dose of COVID-19 BNT162b2 mRNA vaccine in Greek healthcare workers. Microorganisms. 2021;9(8):1725. https://​doi.​org/​10.​3390/​microorganisms90​81725.CrossRefPubMedPubMedCentral

go back to reference Bignucolo A, Scarabel L, Mezzalira S, Polesel J, Cecchin E, Toffoli G. Sex disparities in efficacy in COVID-19 vaccines: a systematic review and meta-analysis. Vaccines (Basel). 2021;9(8):825. https://doi.org/10.3390/vaccines9080825.CrossRef Bignucolo A, Scarabel L, Mezzalira S, Polesel J, Cecchin E, Toffoli G. Sex disparities in efficacy in COVID-19 vaccines: a systematic review and meta-analysis. Vaccines (Basel). 2021;9(8):825. https://​doi.​org/​10.​3390/​vaccines9080825.CrossRef

go back to reference Xie Y, Wang Z, Liao H, Marley G, Wu D, Tang W. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. BMC Infect Dis. 2020;20(1):640. https://doi.org/10.1186/s12879-020-05371-2.CrossRefPubMedPubMedCentral Xie Y, Wang Z, Liao H, Marley G, Wu D, Tang W. Epidemiologic, clinical, and laboratory findings of the COVID-19 in the current pandemic: systematic review and meta-analysis. BMC Infect Dis. 2020;20(1):640. https://​doi.​org/​10.​1186/​s12879-020-05371-2.CrossRefPubMedPubMedCentral

go back to reference Thio CL, Thomas DL, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, O’Brien SJ, Karacki P, Marti D, Astemborski J, Carrington M. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis. 2001;184(1):16–21. https://doi.org/10.1086/321005 (Epub 2001 May 30).CrossRefPubMed Thio CL, Thomas DL, Goedert JJ, Vlahov D, Nelson KE, Hilgartner MW, O’Brien SJ, Karacki P, Marti D, Astemborski J, Carrington M. Racial differences in HLA class II associations with hepatitis C virus outcomes. J Infect Dis. 2001;184(1):16–21. https://​doi.​org/​10.​1086/​321005 (Epub 2001 May 30).CrossRefPubMed

go back to reference Liu G, Carter B, Gifford DK. Predicted cellular immunity population coverage gaps for SARS-CoV-2 subunit vaccines and their augmentation by compact peptide sets. Cell Syst. 2021;12(1):102-107.e4. https://doi.org/10.1016/j.cels.2020.11.010 (Epub 2020 Nov 27).CrossRefPubMed Liu G, Carter B, Gifford DK. Predicted cellular immunity population coverage gaps for SARS-CoV-2 subunit vaccines and their augmentation by compact peptide sets. Cell Syst. 2021;12(1):102-107.e4. https://​doi.​org/​10.​1016/​j.​cels.​2020.​11.​010 (Epub 2020 Nov 27).CrossRefPubMed